HLB Life Science Co. Ltd Asset Resilience Ratio
HLB Life Science Co. Ltd asset resilience ratio. HLB Life Science Co. Ltd (067630) has an Asset Resilience Ratio of 0.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HLB Life Science Co. Ltd (067630) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of HLB Life Science Co. Ltd (2012–2024)
Asset resilience ratio of HLB Life Science Co. Ltd from 2012 to 2024. This chart shows how HLB Life Science Co. Ltd's Asset Resilience Ratio has changed over time. Read HLB Life Science Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down HLB Life Science Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 067630 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩629.30 Million | 0.14% |
| Total Liquid Assets | ₩629.30 Million | 0.14% |
Asset Resilience Insights
- Limited Liquidity: HLB Life Science Co. Ltd maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
HLB Life Science Co. Ltd Industry Peers by Asset Resilience Ratio
Compare HLB Life Science Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 22.68% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
HLB Life Science Co. Ltd Asset Resilience Ratio by Year (2012–2024)
HLB Life Science Co. Ltd asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for HLB Life Science Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.98% | ₩26.84 Billion ≈ $18.19 Million |
₩539.02 Billion ≈ $365.28 Million |
-9.68pp |
| 2023-12-31 | 14.66% | ₩62.09 Billion ≈ $42.08 Million |
₩423.50 Billion ≈ $287.00 Million |
-16.49pp |
| 2022-12-31 | 31.15% | ₩128.27 Billion ≈ $86.93 Million |
₩411.79 Billion ≈ $279.06 Million |
-20.53pp |
| 2021-12-31 | 51.68% | ₩139.96 Billion ≈ $94.85 Million |
₩270.80 Billion ≈ $183.52 Million |
+3.38pp |
| 2020-12-31 | 48.30% | ₩158.03 Billion ≈ $107.10 Million |
₩327.20 Billion ≈ $221.74 Million |
+4.90pp |
| 2019-12-31 | 43.40% | ₩175.76 Billion ≈ $119.11 Million |
₩404.94 Billion ≈ $274.42 Million |
-7.03pp |
| 2018-12-31 | 50.43% | ₩194.79 Billion ≈ $132.01 Million |
₩386.26 Billion ≈ $261.76 Million |
+31.36pp |
| 2017-12-31 | 19.07% | ₩18.89 Billion ≈ $12.80 Million |
₩99.02 Billion ≈ $67.10 Million |
+9.48pp |
| 2016-12-31 | 9.59% | ₩7.93 Billion ≈ $5.37 Million |
₩82.68 Billion ≈ $56.03 Million |
+7.33pp |
| 2015-12-31 | 2.26% | ₩963.40 Million ≈ $652.88K |
₩42.70 Billion ≈ $28.94 Million |
-5.38pp |
| 2014-12-31 | 7.63% | ₩2.55 Billion ≈ $1.73 Million |
₩33.39 Billion ≈ $22.63 Million |
+1.72pp |
| 2013-12-31 | 5.91% | ₩2.85 Billion ≈ $1.93 Million |
₩48.23 Billion ≈ $32.68 Million |
-1.62pp |
| 2012-12-31 | 7.53% | ₩3.45 Billion ≈ $2.34 Million |
₩45.87 Billion ≈ $31.08 Million |
-- |
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more